1 / 2

Étude ASPECCT

Étude ASPECCT. Survie globale. Événements n/N (%). Médiane (IC 95 ) Mois. 100. 383/499 (76,8). 10,4 (9,4-11,6). Panitumumab. 80. Cétuximab. 392/500 (78,4). 10,0 (9,3-11,0). 60. Survie globale (%). HR = 0,97 ; IC 95 : 0,84-1,11 p = 0,0007 Z-score = -3,19

jadon
Télécharger la présentation

Étude ASPECCT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Étude ASPECCT Survie globale Événementsn/N (%) Médiane (IC95)Mois 100 383/499 (76,8) 10,4 (9,4-11,6) Panitumumab 80 Cétuximab 392/500 (78,4) 10,0 (9,3-11,0) 60 Survie globale (%) HR = 0,97 ; IC95 : 0,84-1,11p = 0,0007Z-score = -3,19 Taux de rétention = 1,06 ; IC95 : 0,82-1,29 40 20 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 Mois Patients à risque Cétuximab Panitumumab 500 499 462 456 398 399 349 345 283 286 221 224 181 185 151 156 122 124 94 98 70 76 54 48 37 32 24 22 16 12 8 3 1 2 0 2 0 0 • ESMO 2013 - D’après Price T et al., LBA 18, actualisé • La Lettre du Cancérologue

  2. Étude ASPECCT Survie sans progression Événementsn/N (%) Médiane (IC95)Mois 100 477/499(95,6) 4,1 (3,2-4,8) Panitumumab 80 Cétuximab 477/500 (95,4) 4,4 (3,2-4,8) 60 Survie sans progression (%) 40 HR = 1,002 ; IC95 : 0,882-1,138 20 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 Mois Patients à risque Cétuximab Panitumumab 500 499 355 350 247 245 155 151 86 73 41 42 23 27 15 16 9 9 4 7 3 6 1 3 1 3 0 2 0 2 0 1 0 0 • La Lettre du Cancérologue • ESMO 2013 - D’après Price T et al., LBA 18, actualisé

More Related